Kyowa Kirin Co., Ltd.
Kyowa Kirin is a Japanese global specialty pharmaceutical company developing and commercializing medicines for serious and often underserved conditions. Its research capabilities include antibody-based medicines and other biologic or targeted therapeutic approaches supported by clinical development and specialized manufacturing. The company has long worked in rare diseases and selected hematology and immunology markets. Based in Japan, Kyowa Kirin is listed on the Tokyo Stock Exchange under security code 4151. This directory records its stable therapeutic activities and technology orientation, without attempting to track every product indication or licensing agreement.
Company at a glance
Corporate information
- Company entity
- Kyowa Kirin Co., Ltd.
- Headquarters / principal office
- Japan
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.kyowakirin.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
TSE: 4151
antibody medicines · specialty biologics
rare diseases · hematology · immunology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Kyowa Kirin is a Japanese global specialty pharmaceutical company developing and commercializing medicines for serious and often underserved conditions. Its research capabilities include antibody-based medicines and other biologic or targeted therapeutic approaches supported by clinical development and specialized manufacturing. The company has long worked in rare diseases and selected hematology and immunology markets. Based in Japan, Kyowa Kirin is listed on the Tokyo Stock Exchange under security code 4151. This directory records its stable therapeutic activities and technology orientation, without attempting to track every product indication or licensing agreement.
Business, technology & evidence
- SecuritiesTSE: 4151
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Kyowa Kirin Co., Ltd. ↗Kyowa Kirin Co., Ltd. ·
- Official issuer and R&D disclosure · Kyowa Kirin Co., Ltd. ↗Kyowa Kirin Co., Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.